A recent randomized controlled trial published in BMC Cancer demonstrated that a 10 mg dose of dexamethasone is non-inferior to higher doses in preventing hypersensitivity reactions (HSRs) from paclitaxel chemotherapy. This finding supports dose reduction strategies to minimize corticosteroid-associated adverse effects while maintaining prophylactic efficacy in oncology practice, potentially improving patient tolerance and safety profiles during cancer treatment.